{"schema_version":"1","generated_at":"2026-11-21T17:48:39.097Z","data_as_of":null,"url":"https://www.findmykol.com/kol/merideth-wendland","json_url":"https://www.findmykol.com/kol/merideth-wendland/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"merideth-wendland","name":"Merideth Wendland","credential":"MD","specialty":"Radiation Oncology","specialty_raw":"Radiation Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Willamette Valley Cancer Institute and Research Center","institution_url":"https://www.findmykol.com/institution/willamette-valley-cancer-institute-and-research-center","city":"Eugene","state":"OR","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Merideth Wendland is an Oncology physician affiliated with Willamette Valley Cancer Institute and Research Center. OpenAlex indexes 39 publications with 2,072 citations (h-index 16).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":39,"cited_by_count":2072,"h_index":16,"latest_activity_year":2024,"source":"works"},"prescribing":{"data_year":2021,"areas_total":1,"areas_shown":1,"areas":[{"area":"Respiratory","share_pct":100,"classes_total":1,"classes":[{"class":"Opioid Agonist","setting":"prescribed","share_pct":100,"drugs":[{"name":"Hydrocodone-Acetaminophen","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2021,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":39,"shown":5,"withheld":34,"matched_by":"OpenAlex author record","recent":[{"title":"Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825","year":2024,"journal":"Neuro-Oncology","source_url":"https://doi.org/10.1093/neuonc/noae234","status":"verified"},{"title":"Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825","year":2022,"journal":"Neuro-Oncology Advances","source_url":"https://doi.org/10.1093/noajnl/vdac152","status":"verified"},{"title":"NCOG-20. BRAIN ATROPHY IN GLIOBLASTOMA PATIENTS FOLLOWING TREATMENT WITH CHEMORADIATION OR CHEMORADIATION WITH ANTI-ANGIOGENIC THERAPY IN NRG/RTOG 0825 PARTICIPANTS","year":2022,"journal":"Neuro-Oncology","source_url":"https://doi.org/10.1093/neuonc/noac209.773","status":"verified"},{"title":"Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)","year":2021,"journal":"Neuro-Oncology","source_url":"https://doi.org/10.1093/neuonc/noab011","status":"verified"},{"title":"Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825","year":2021,"journal":"Journal of Neuro-Oncology","source_url":"https://doi.org/10.1007/s11060-021-03886-5","status":"verified"}],"source":"works"},"similar":[{"name":"Jeff Sharman","slug":"jeff-sharman","institution":"Willamette Valley Cancer Institute and Research Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jeff-sharman","json_url":"https://www.findmykol.com/kol/jeff-sharman/profile.json"},{"name":"James Butrynski","slug":"james-butrynski","institution":"Willamette Valley Cancer Institute and Research Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/james-butrynski","json_url":"https://www.findmykol.com/kol/james-butrynski/profile.json"},{"name":"Christopher Yasenchak","slug":"christopher-yasenchak","institution":"Willamette Valley Cancer Institute and Research Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christopher-yasenchak","json_url":"https://www.findmykol.com/kol/christopher-yasenchak/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":34}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2021}},"methodology_url":"https://www.findmykol.com/about#methodology"}